Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases.

There was no difference in the risk of infield cancer persistence regardless of the pre-irreversible electroporation ISUP score (p = 0.8), or tumour location (p > 0.9).

The presence of low volume out-of-field cancer at diagnosis did not increase the risk of post-irreversible electroporation cancer persistence/progression (p = 0.7).

The prostate PSMA PET SUVmax of ≥10 did not increase the risk of infield or out-of-field recurrence of cancer (p = 0.3).

A PSAD > 0.15 did not increase the risk of infield persistence or out-of-field progression of cancer (p = 0.8).